Aktie A0NBM2 CHEMOCENTRYX, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen ChemoCentryx, Inc.

Aktien

A0NBM2

US16383L1061

CCXI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Global BMI Index
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P TMI Index
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Biotechnology Select Industry Index
HBM Healthcare confirme une perte semestrielle de 34,2 millions
Amgen Completes ChemoCentryx Acquisition
CHEMOCENTRYX, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
Chemocentryx, Inc. Announces Executive Changes
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Composite Index
Amgen Inc. completed the acquisition of ChemoCentryx, Inc. from a group of shareholders.
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Biotechnology Index
CHEMOCENTRYX, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
HBM Healthcare prévoit une perte de 34 millions au 1er semestre 2022/23
Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease
CHEMOCENTRYX, INC. : Other Events (form 8-K)
ChemoCentryx Announces TAVNEOS (avacopan) Presentations at Upcoming Medical Conferences
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A0NBM2 Aktie
  4. Nachrichten ChemoCentryx, Inc.
  5. Andere Sprachen